DURECT (DRRX)
(Delayed Data from NSDQ)
$1.67 USD
-0.01 (-0.30%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.67 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
DURECT Corporation [DRRX]
Reports for Purchase
Showing records 21 - 40 ( 143 total )
Company: DURECT Corporation
Industry: Medical - Drugs
First European Patient Dosed in Lead Phase 2b Study in Severe Alcoholic Hepatitis; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
We See Clear Synergies in Licensing POSIMIR to Innocoll in Order to Maximize its Sales Potential; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
First Ex-U.S. Patient Dosing Begins in Phase 2b AHFIRM Study of Larsucosterol for Severe AH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
3Q21 Recap; AHFIRM Continues Expansion Into New Clinical Sites; DUR-928 Officially Named Larsucosterol; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
2Q21 Recap: DUR-928 Phase 2b AHFIRM Clinical Sites to Expand Beyond U.S. in 2H21; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
1Q21 Recap; DUR-928 Mechanism of Action As Epigenetic Regulator Underlies Effectiveness in AH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
4Q20 Recap: With POSIMIR Approved and Recent Raise, Focus Tightens on AH Opportunity; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
Potentially Pivotal Phase 2b AHFIRM Study in Severe AH Underway; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
FDA Fast Track Designation Points to Potential for Rapid Full Approval Timeline for DUR-928; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
DURECT Monetizes LACTEL Product Line For $15M, Consolidating Focus on DUR-928; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
AHFIRM May Affirm DUR-928''s Potential as the New Treatment Paradigm for Severe AH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
3Q20 Recap; Expecting a Busy 2021 for DUR-928 in Three Indications; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
We are initiating coverage of DURECT Corporation with a Buy rating and 12-month Price Target of $7/share.
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E